Request a copy

Full Text

20

CITATIONS

20 Total citations

1 Recent citation

2.49 Field Citation Ratio

1.4 Relative Citation Ratio

publications

0

supporting

0

mentioning

0

contrasting

0

Smart Citations

0

0

0

0

Citing PublicationsSupportingMentioningContrasting

View Citations

See how this article has been cited at scite.ai

scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.

• [1] Kawabata, Y., Wada, K., Nakatani, M., Yamada, S., Onoue, S., Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: basic approaches and practical applications. Int. J. Pharm. 420 (2011), 1–10.
• [2] Pestieau, A., Krier, F., Lebrun, P., Brouwers, A., Streel, B., Evrard, B., Optimization of a PGSS (particles from gas saturated solutions) process for a fenofibrate lipid-based solid dispersion formulation. Int. J. Pharm. 485 (2015), 295–305.
• [3] Phillips, D.J., Pygall, S.R., Cooper, V.B., Mann, J.C., Overcoming sink limitations in dissolution testing: a review of traditional methods and the potential utility of biphasic systems. J. Pharm. Pharmacol. 64 (2012), 1549–1559.
• [4] Long, M., Chen, Y., Chapter 14 - Dissolution Testing of Solid Products. Developing Solid Oral Dosage Forms: Pharmaceutical Theory and Practice, 2009, Academic Press, San Diego, 319–340.
• [5] FDA, Extended Release Oral Dosage Forms: Development, Evaluation, and Application of In Vitro/In vivo Correlations, Guidance for Industry - Extended Release Oral Dosage Forms: Development, Evaluation, and Application of In Vitro/In vivo Correlations, 1997.
• [6] FDA, Q8 (R2) Pharmaceutical Development, Guidance for Industry - Q8 (R2) Pharmaceutical Development, 2009.
• [7] Qiu, Y., Chapter 17 - In Vitro–In Vivo Correlations: Fundamentals, Development Considerations, and Applications. Porter, Y.Q.C.G.Z.Z.L.R., (eds.) Developing Solid Oral Dosage Forms, 2009, Academic Press, San Diego, 379–406.
• [8] Thomas, N., Richter, K., Pedersen, T., Holm, R., Müllertz, A., Rades, T., In vitro lipolysis data does not adequately predict the in vivo performance of lipid-based drug delivery systems containing fenofibrate. The AAPS J. 16 (2014), 539–549.
• [9] Griffin, B.T., Kuentz, M., Vertzoni, M., Kostewicz, E.S., Fei, Y., Faisal, W., Stillhart, C., O'Driscoll, C.M., Reppas, C., Dressman, J.B., Comparison of in vitro tests at various levels of complexity for the prediction of in vivo performance of lipid-based formulations: case studies with fenofibrate. Eur. J. Pharm. Biopharm. 86 (2014), 427–437.
• [10] Kollipara, S., Gandhi, R.K., Pharmacokinetic aspects and in vitro–in vivo correlation potential for lipid-based formulations. Acta Pharmaceutica Sinica B 4 (2014), 333–349.
• [11] Lue, B.-M., Nielsen, F.S., Magnussen, T., Schou, H.M., Kristensen, K., Jacobsen, L.O., Müllertz, A., Using biorelevant dissolution to obtain IVIVC of solid dosage forms containing a poorly-soluble model compound. Eur. J. Pharm. Biopharm. 69 (2008), 648–657.
• [12] Borkar, N., Xia, D., Holm, R., Gan, Y., Müllertz, A., Yang, M., Mu, H., Investigating the correlation between in vivo absorption and in vitro release of fenofibrate from lipid matrix particles in biorelevant medium. Eur. J. Pharm. Sci. 51 (2014), 204–210.
• [13] Do, T.T., Van Speybroeck, M., Mols, R., Annaert, P., Martens, J., Van Humbeeck, J., Vermant, J., Augustijns, P., Van den Mooter, G., The conflict between in vitro release studies in human biorelevant media and the in vivo exposure in rats of the lipophilic compound fenofibrate. Int. J. Pharm. 414 (2011), 118–124.
• [14] Grundy, J.S., Anderson, K.E., Rogers, J.A., Foster, R.T., Studies on dissolution testing of the nifedipine gastrointestinal therapeutic system. I. Description of a two-phase in vitro dissolution test. J. Control. Release 48 (1997), 1–8.
• [15] Grundy, J.S., Anderson, K.E., Rogers, J.A., Foster, R.T., Studies on dissolution testing of the nifedipine gastrointestinal therapeutic system. II. Improved in vitro-in vivo correlation using a two-phase dissolution test. J. Control. Release 48 (1997), 9–17.
• [16] Shi, Y., Gao, P., Gong, Y., Ping, H., Application of a biphasic test for characterization of in vitro drug release of immediate release formulations of celecoxib and its relevance to in vivo absorption. Mol. Pharm. 7 (2010), 1458–1465.
• [17] Pestieau, A., Krier, F., Brouwers, A., Streel, B., Evrard, B., Selection of a discriminant and biorelevant in vitro dissolution test for the development of fenofibrate self-emulsifying lipid-based formulations. Eur. J. Pharm. Sci. 92 (2016), 212–219.
• [18] Al Durdunji, A., AlKhatib, H.S., Al-Ghazawi, M., Development of a biphasic dissolution test for Deferasirox dispersible tablets and its application in establishing an in vitro–in vivo correlation. Eur. J. Pharm. Biopharm. 102 (2016), 9–18.
• [19] F.D.A. US Department of Health and Human Services, Center for Drug Evaluation and Research, Guidance for Industry: Dissolution Testing of Immediate Release Solid Oral Dosage Forms, 1997.
• [20] Diehl, K.-H., Hull, R., Morton, D., Pfister, R., Rabemampianina, Y., Smith, D., Vidal, J.-M., Vorstenbosch, C.V.D., A good practice guide to the administration of substances and removal of blood, including routes and volumes. J. Appl. Toxicol. 21 (2001), 15–23.
• [21] Horkovics-Kovats, S., Efficiency of enterohepatic circulation, its determination and influence on drug bioavailability. Arzneimittelforschung 49 (1999), 805–815.
• [22] Cardot, J.M., Davit, B.M., In vitro–in vivo correlations: tricks and traps. AAPS J. 14 (2012), 491–499.